ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,302.57
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,589.02
1.11%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Nymox Pharmaceutical Corp (NYMX)

  7. Nymox Pharmaceutical Corp (NYMX) News

Nymox Pharmaceutical (NYMX)

Nymox Pharmaceutical Corp
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NYMX
DateTimeSourceHeadlineSymbolCompany
28/03/202417:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
09/11/202317:55Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
06/11/202314:59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
26/10/202320:31Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
08/09/202315:13Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:NYMXNymox Pharmaceutical Corp
29/08/202320:34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
02/08/202318:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
31/07/202318:54Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
25/07/202321:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
25/07/202321:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
25/07/202315:33GlobeNewswire Inc.Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial ResultsNASDAQ:NYMXNymox Pharmaceutical Corp
18/07/202315:45GlobeNewswire Inc.Nymox Reports on U.S. Patent IssuancesNASDAQ:NYMXNymox Pharmaceutical Corp
13/07/202315:16GlobeNewswire Inc.Nymox UpdateNASDAQ:NYMXNymox Pharmaceutical Corp
12/07/202322:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
12/07/202314:30GlobeNewswire Inc.Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of NymoxNASDAQ:NYMXNymox Pharmaceutical Corp
07/07/202322:02GlobeNewswire Inc.NYMOX UpdateNASDAQ:NYMXNymox Pharmaceutical Corp
05/07/202323:11GlobeNewswire Inc.Nymox Delisting from NASDAQNASDAQ:NYMXNymox Pharmaceutical Corp
29/06/202322:15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NYMXNymox Pharmaceutical Corp
29/06/202322:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
29/06/202321:25Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:NYMXNymox Pharmaceutical Corp
29/06/202321:24Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:NYMXNymox Pharmaceutical Corp
27/06/202322:15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NYMXNymox Pharmaceutical Corp
26/06/202315:28Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:NYMXNymox Pharmaceutical Corp
18/05/202321:14Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:NYMXNymox Pharmaceutical Corp
12/05/202321:53Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NYMXNymox Pharmaceutical Corp
10/05/202315:00GlobeNewswire Inc.Nymox Provides Current UpdateNASDAQ:NYMXNymox Pharmaceutical Corp
03/04/202314:30GlobeNewswire Inc.Nymox Provides Corporate UpdateNASDAQ:NYMXNymox Pharmaceutical Corp
31/03/202321:25Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:NYMXNymox Pharmaceutical Corp
21/03/202314:00GlobeNewswire Inc.Nymox Announces Appointment of Christopher R. Riley as Chief Financial OfficerNASDAQ:NYMXNymox Pharmaceutical Corp
15/03/202313:30GlobeNewswire Inc.Nymox Officially Granted Extension to Regain Listing RequirementsNASDAQ:NYMXNymox Pharmaceutical Corp
 Showing the most relevant articles for your search:NASDAQ:NYMX

Your Recent History

LSE
SCLP
Scancell
LSE
AGL
Angle
LSE
EEE
Empire Metals
LSE
SCE
Surface Transforms
LSE
FUM
Futura Medical
LSE
MIN
Minoan
LSE
SRSP
Sirius Petroleum
LSE
GFM
Griffin Mining
LSE
AAU
Ariana Resources
LSE
TERN
Tern
LSE
ENET
Ethernity Networks
LSE
JAY
Bluejay Mining
LSE
YU.
Yu
LSE
PHNX
Phoenix
LSE
GKP
Gulf Keystone Petroleum
LSE
ZPHR
Zephyr Energy
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved